Target intelligence / Profile preview

Teashirt zinc finger homeobox 2 (TSHZ2)

Target
TSHZ2
Molecular classification
Transcription factor, Zinc finger protein, Homeobox protein
01

Overview

Teashirt zinc finger homeobox 2 (TSHZ2) is a nuclear transcription factor containing multiple zinc finger motifs and a homeobox domain[1][3]. It acts predominantly as a transcriptional repressor in association with C-terminal binding protein (CtBP), especially CtBP2[1][2]. TSHZ2 can inhibit oncogenic pathways by repressing downstream genes such as AEBP1 and CXCR4 and by inhibiting the transcription factor GLI1[1][2]. It interacts with several cell cycle regulators, including PRC1, KIF4A, and cyclin B1—implicating it in the control of mitosis and cytokinesis[2]. In normal tissues, TSHZ2 is expressed in the cell nucleus and is often found down-regulated in cancer, including breast and lung adenocarcinomas, where loss of expression associates with increased proliferation, invasion, and poor prognosis[1][2][3]. There are no known drugs that directly target TSHZ2, and its mechanisms of drug interaction, if any, have not been established. The gene and protein are well-characterized transcriptional repressors and tumor suppressors, but are not therapeutic targets for drugs as of current research, despite being critically relevant in cancer biology[1][2][3].

Other names
Teashirt homolog 2C20orf17TSH2ZNF218OVC10-2ZABC2zinc finger protein 218ovarian cancer-related protein 10-2cell growth-inhibiting protein 7serologically defined colon cancer antigen 33 liketeashirt family zinc finger 2
02

Biological functions

Transcriptional repressionRegulation of cell proliferationTumor suppressionCytokinesis regulationChromatin organization
03

Disease associations

Cancer (notably breast, lung, ovarian)Potential tumor suppressor in various malignancies
04

Safety considerations

No specific therapeutic safety concerns known; as a tumor suppressor, the primary concern would be on-target loss of function, which may promote tumorigenesis[1][2][3]
05

Biomarkers

Low TSHZ2 expression has been associated with poor prognosis in some cancers, notably breast and lung adenocarcinoma[1][3]

Beyond the preview

Go deeper on Teashirt zinc finger homeobox 2 (TSHZ2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teashirt zinc finger homeobox 2 (TSHZ2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call